Torsten Haferlach - Concepedia

Author

Torsten Haferlach

Munich Leukemia Laboratory (Germany)ORCID

Also Known As

AML Cooperative Group and ECOG, Adolfo A. Ferrando, German AML Cooperative Group, H. Löffler, Haferlach T., Haferlach Torsten, Haferlach, Torsten, Irmela Jeremias, Karsten Spiekermann, M. Dugas

Publications

60.5K

Citations

118

H-Index

186

Concepts

All Affiliations

Munich Leukemia Laboratory (Germany)Ludwig-Maximilians-Universität München Heidelberg University University Hospital Heidelberg University of Münster

About

Torsten Haferlach is an author at Munich Leukemia Laboratory (Germany) specializing in medicine, hematology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	63	172	18.2K
2	Health Sciences	24	40	3.1K
3	Engineering	18	21	1.4K
4	Language Studies	1	1	63
5	Management	1	1	28

Torsten Haferlach

414

Publications

45.3K

Citations

110

H-Index

Page 1

	Year	Citations
Frequent pathway mutations of splicing machinery in myelodysplasia Kenichi Yoshida, Masashi Sanada, Yuichi Shiraishi, Nature GeneticsMolecular GeneticsFrequent Pathway MutationsGene ExpressionMedicine	2011	2K
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes Torsten Haferlach, Yasunobu Nagata, Vera Grossmann, Leukemia Genetic LesionsHematological MalignancyGenetic AberrationsGenetic DisorderMedicine	2013	1.5K
<i>BRAF</i> Mutations in Hairy-Cell Leukemia Enrico Tiacci, Gianluca Schiavoni, Antony B. Holmes, New England Journal of Medicine	2011	1K
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease Susanne Schnittger, Claudia Schoch, Martin Dugas, Blood	2002	962
Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes Peter Valent, Amy D. Klion, Hans‐Peter Horny, Journal of Allergy and Clinical Immunology Eosinophilic DisordersPsychiatryClinical EpidemiologyPediatricsEosinophilic Disorder	2012	747
Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia Rongqing Pan, Leah J. Hogdal, Juliana M. Benito, Cancer Discovery	2013	717
Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype Susanne Schnittger, Claudia Schoch, Wolfgang Kern, Blood	2005	701
Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Subclassification of Leukemia: Report From the International Microarray Innovations in Leukemia Study Group Torsten Haferlach, Alexander Kohlmann, Lothar Wieczorek, Journal of Clinical Oncology	2010	668
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party Michael Heuser, Sylvie Freeman, Gert J. Ossenkoppele, Blood Mixed-phenotype Acute LeukemiaPathologyMeasurable Residual DiseaseMyeloid NeoplasiaHematological Malignancy	2021	666
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With <i>FLT3</i>–Internal Tandem Duplication Mutation (SORMAIN) Andreas Burchert, Gesine Bug, Lea Fritz, Journal of Clinical Oncology	2020	538

Page 1